Synodos for NF2 Consortium publishes key outcomes of its work (News)


The Synodos for NF2 consortium of the Kids’s Tumor Basis (CTF) immediately revealed its first set of outcomes and launched its second set of information within the main scientific journal PLOS ONE. Synodos is the Basis’s progressive staff science collaborative that brings researchers, clinicians and sufferers collectively in a shared information atmosphere, as a way to develop therapies for NF sufferers at an accelerated tempo. Established in 2014, the $Three million challenge is a mixed effort amongst 12 main analysis labs at eight establishments.

The Synodos for NF2 staff launched its first set of outcomes and information within the scientific journal PLOS ONE, entitled Conventional and Techniques Biology Based mostly Drug Discovery for the Uncommon Tumor Syndrome Neurofibromatosis Sort 2. According to the Basis’s ideas of open-access and information sharing, the journal is making the complete article out there to all, with fast entry to the information.

The first intention of the Synodos for NF2 staff was to search out therapies that may very well be used for each meningioma and schwannoma through the use of a drug discovery strategy of choosing mechanistically related compounds. The staff built-in progressive analysis approaches equivalent to Subsequent Technology Sequencing (NGS) and Kinome profiling. These two methods permit evaluation of the alteration in expression of genes and proteins in cells or animal fashions.

A core discovering was that whereas schwannomas and meningiomas are each initiated by merlin loss, the distinctly totally different responses to that lack of operate are more likely to prescribe {that a} single drug (goal) is unlikely to be optimally efficient in each cell sorts. As an alternative, it’s probably that totally different medication or combos (a cocktail of two or extra medication) geared toward distinct targets can be required to deal with these two tumor sorts. In actual fact, the primary three single medication examined (Panobinostat, CUDC-907 and GSK2126458) have been solely mildly energetic in stopping tumors from rising. The following set of experiments began drug combos and the staff reported that the drug Dasatininb, a multi-kinase inhibitor together with AZD-2014 or INK128, each twin mTORC1/2 inhibitors, suppressed tumor development as much as ~85% in a meningioma animal mannequin (this final outcome was reported earlier in March 2018 by the Synodos staff within the scientific journal Neuro-Oncology. That publication might be discovered right here:

Moreover, the work of the Synodos for NF2 consortium has crammed a crucial hole within the understanding of how the NF2 mutation and the absence of merlin affect tumor cell conduct in each meningiomas and schwannomas. The collective effort of twelve analysis teams succeeded in:

    (1) creating a brand new pipeline of well-validated instruments for NF2-associated drug discovery with absolutely characterised isogenic pairs of meningioma and schwannoma cell methods;

    (2) gaining conceptual insights into illness mechanisms by way of transcriptome and kinome interrogation that point out that totally different medication are more likely to be wanted to deal with meningioma and schwannoma;

    (3) validating pathways and targets which can be altered primarily based on tumor sort and in response to focused pathway inhibition within the setting of NF2; and

    (4) constructing an overtly accessible database for neighborhood sharing and mining of drug remedy, transcriptome and kinome information from isogenic schwannoma and meningioma cell methods. This information presents a number of targets to think about for single agent and mixture remedy within the quick time period, and supplies a deep and wealthy open entry information useful resource for the broader analysis neighborhood in search of therapies for NF2-associated meningioma and schwannoma for the long run.

The Synodos staff is actively engaged on finalizing the newest findings, which may even be revealed as a comply with as much as this analysis launch.

In the end, these newly launched outcomes and information are offering, for the primary time, a crucial useful resource that can be invaluable to the NF2 analysis neighborhood. This work illustrates that the CTF mannequin of bringing collectively scientists of numerous experience areas improves the flexibility to find new therapeutic methods to deal with these extremely devastating tumors.

The total article in PLOS ONE might be discovered right here:



The Kids’s Tumor Basis is a 501(c)(3) not-for-profit group devoted to funding and driving progressive analysis that may end in efficient therapies for the tens of millions of individuals worldwide dwelling with neurofibromatosis (NF), a time period for 3 distinct issues: NF1, NF2, and schwannomatosis. NF causes tumors to develop on nerves all through the physique and will result in blindness, deafness, bone abnormalities, disfigurement, studying disabilities, disabling ache, and most cancers. NF impacts 1 in each 3,000 births throughout all populations equally. There isn’t any treatment but – however the Kids’s Tumor Basis mission of driving analysis, increasing information, and advancing look after the NF neighborhood fosters our imaginative and prescient of at some point ending NF. For extra data, please go to


Simon Vukelj

Vice President, Advertising and Communications

Kids’s Tumor Basis

(212) 344-7568

[email protected]

Disclaimer: AAAS and EurekAlert! are usually not liable for the accuracy of News releases posted to EurekAlert! by contributing establishments or for using any data by means of the EurekAlert system.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.